12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

IPX066 regulatory update

FDA accepted for review an NDA from Impax for IPX066 to treat idiopathic Parkinson's disease (PD). The compound is an extended-release...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >